Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

19.16
-1.4900-7.22%
Post-market: 19.540.3800+1.98%19:25 EST
Volume:1.89M
Turnover:36.68M
Market Cap:824.29M
PE:40.65
High:20.84
Open:20.51
Low:18.92
Close:20.65
52wk High:27.64
52wk Low:18.92
Shares:43.02M
Float Shares:37.84M
Volume Ratio:1.24
T/O Rate:4.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4713
EPS(LYR):-2.1529
ROE:2.90%
ROA:2.89%
PB:1.13
PE(LYR):-8.90

Loading ...

Pacira Biosciences Inc - to Receive Upfront Payment and Royalties From LG Chem

THOMSON REUTERS
·
Jan 13

Pacira Biosciences Inc - LG Chem Gains Exclusive Rights to Commercialize Exparel

THOMSON REUTERS
·
Jan 13

Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

GlobeNewswire
·
Jan 13

Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist Pressure - Has The Bull Case Changed?

Simply Wall St.
·
Jan 12

Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure

Simply Wall St.
·
Jan 10

Stock Track | Pacira Pharmaceuticals Plummets 13.37% Intraday After Reporting Preliminary FY25 Revenue Results

Stock Track
·
Jan 10

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

Benzinga
·
Jan 10

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Pacira Pharmaceuticals (PCRX) and Beta Bionics, Inc. (BBNX)

TIPRANKS
·
Jan 09

Pacira BioSciences Is Maintained at Buy by Needham

Dow Jones
·
Jan 09

Stocks to Watch: Cemtrex, Olin, Pacira BioSciences, Tilray Brands

Dow Jones
·
Jan 09

Pacira BioSciences Falls After Preliminary Sales Miss Estimates

Dow Jones
·
Jan 09

Pacira 2025 preliminary revenue slightly misses expectations

Reuters
·
Jan 09

Pacira Biosciences FY Revenue USD 726.4 Million VS. Ibes Estimate USD 737.8 Million

THOMSON REUTERS
·
Jan 09

Press Release: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Dow Jones
·
Jan 09

It’s Earnings Warning Season. How to Profit From Others’ Misery

Dow Jones
·
Jan 01

Update: Pacira Biosciences Shareholder Seeks Board Changes, Pushes for Sale

MT Newswires Live
·
Jan 01

BRIEF-Doma Perpetual Capital Management Asserts Pacira Biosciences's Board To Pursue Sale Of Company

Reuters
·
Dec 30, 2025

Doma Perpetual Capital Management: Asserts Pacira Biosciences's Board of Directors Should Pursue an Immediate Sale of Company

THOMSON REUTERS
·
Dec 30, 2025

Press Release: DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

Dow Jones
·
Dec 30, 2025

Pacira BioSciences (PCRX): How the New PROBE Consortium Partnership Shapes Its Current Valuation

Simply Wall St.
·
Dec 26, 2025